title: Current status of melanoma chemotherapy and immunotherapy.
abstract: In the search for an improved prognosis in malignant melanoma after radical surgery, randomized trials arae being conducted examining the results of immunostimulation (BCG or levamisole) with chemotherapy dimethyl - triazeno - imidazole - carboxamide (DTIC) in stage I melanoma. So far, no significant differences between the groups are evident. In stage III melanoma, a series of new agents are being rapidly screened and some appear promising. A closer look at the basic immunopathologic process during the growth of melanomas is might lead to a more effective control of this malignancy.
mesh_terms: D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D007978:Levamisole / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy / Q000628:therapy* / Q000648:ultrastructure; D008854:Microscopy, Electron; D009163:Mycobacterium bovis / Q000276:immunology; D009367:Neoplasm Staging
chemical_list: D007978:Levamisole; D003606:Dacarbazine